IRIS
ETTARI, Roberta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.721
NA - Nord America 4.335
AS - Asia 3.284
SA - Sud America 1.137
AF - Africa 115
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 2
AN - Antartide 1
Totale 15.599
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.229
RU - Federazione Russa 3.638
SG - Singapore 1.386
BR - Brasile 972
CN - Cina 878
IE - Irlanda 804
IT - Italia 624
SE - Svezia 601
HK - Hong Kong 386
VN - Vietnam 225
DE - Germania 196
FR - Francia 196
GB - Regno Unito 130
PL - Polonia 124
IN - India 106
UA - Ucraina 105
FI - Finlandia 103
AT - Austria 78
BD - Bangladesh 52
AR - Argentina 50
CA - Canada 44
MX - Messico 42
IQ - Iraq 37
TR - Turchia 32
MA - Marocco 30
ZA - Sudafrica 30
NL - Olanda 28
BE - Belgio 27
ID - Indonesia 26
EC - Ecuador 25
UZ - Uzbekistan 22
CO - Colombia 21
JP - Giappone 20
VE - Venezuela 19
ES - Italia 16
PK - Pakistan 16
UY - Uruguay 15
PY - Paraguay 13
SA - Arabia Saudita 13
TN - Tunisia 13
AE - Emirati Arabi Uniti 11
CL - Cile 10
CZ - Repubblica Ceca 10
DZ - Algeria 8
GE - Georgia 8
PE - Perù 7
AZ - Azerbaigian 6
KE - Kenya 6
KZ - Kazakistan 6
LT - Lituania 6
PH - Filippine 6
BO - Bolivia 5
CI - Costa d'Avorio 5
DO - Repubblica Dominicana 5
EG - Egitto 5
ET - Etiopia 5
IL - Israele 5
JM - Giamaica 5
LB - Libano 5
MY - Malesia 5
CH - Svizzera 4
JO - Giordania 4
KG - Kirghizistan 4
LV - Lettonia 4
NI - Nicaragua 4
SC - Seychelles 4
AL - Albania 3
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
EU - Europa 3
GR - Grecia 3
KR - Corea 3
KW - Kuwait 3
NP - Nepal 3
SY - Repubblica araba siriana 3
AM - Armenia 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BY - Bielorussia 2
GA - Gabon 2
HN - Honduras 2
MD - Moldavia 2
MU - Mauritius 2
RO - Romania 2
RS - Serbia 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
AO - Angola 1
AQ - Antartide 1
AU - Australia 1
CR - Costa Rica 1
EE - Estonia 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LY - Libia 1
MK - Macedonia 1
ML - Mali 1
MM - Myanmar 1
Totale 15.588
Salva come PNG Salva come JPEG
Città #
Moscow 1.058
Dublin 804
Singapore 733
Ashburn 685
Chandler 547
Nyköping 433
Hong Kong 385
Dallas 354
Beijing 330
Messina 257
Jacksonville 228
The Dalles 134
San Jose 130
Princeton 127
Warsaw 122
Medford 114
Lauterbourg 110
Los Angeles 97
Des Moines 91
Dearborn 90
Cambridge 81
São Paulo 73
Ann Arbor 71
Vienna 71
Ho Chi Minh City 70
Buffalo 58
New York 54
Redondo Beach 51
Tianjin 47
Hanoi 45
Boardman 39
Frankfurt am Main 34
Lancaster 33
Rio de Janeiro 33
Guangzhou 31
Munich 31
Jinan 30
San Mateo 30
Santa Clara 27
Hyderabad 24
Orem 24
Brussels 23
Montreal 23
Belo Horizonte 22
Rome 21
Stockholm 21
Tashkent 21
Aversa 20
Curitiba 20
Amsterdam 18
Brooklyn 18
Tokyo 18
Wilmington 18
Brasília 17
Baghdad 16
Campinas 16
Chicago 16
Porto Alegre 16
Pune 16
Houston 15
San Francisco 15
Seattle 15
Shenzhen 15
Johannesburg 14
Milan 14
Shanghai 14
Shenyang 14
Chennai 13
Council Bluffs 13
Denver 13
London 13
Mexico City 13
Woodbridge 13
Atlanta 12
Boston 12
Düsseldorf 12
Montevideo 12
Montpellier 12
Mumbai 12
Casablanca 11
Taizhou 11
Augusta 10
Dong Ket 10
Guarulhos 10
Haikou 10
Helsinki 10
Nanjing 10
Nuremberg 10
Palermo 10
Phoenix 10
Uberlândia 10
Zhengzhou 10
Bari 9
Biên Hòa 9
Da Nang 9
Hebei 9
Manaus 9
Poplar 9
Ankara 8
Catania 8
Totale 8.594
Salva come PNG Salva come JPEG
Nome #
BAY 11-7082 inhibits the NF-κB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis 235
Exploiting Curcumin Synergy With Natural Products Using Quantitative Analysis of Dose–Effect Relationships in an Experimental In Vitro Model of Osteoarthritis 199
Design, synthesis and biological evaluation of novel rhodesain inhibitors for the treatment of Human African Trypanosomiasis 190
Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors 184
Constrained peptidomimetics as antiplasmodial falcipain-2 inhibitors 175
Design, synthesis and biological evaluation of novel dipeptide-like rhodesain inhibitors containing a conformationally constrained 3-bromoisoxazoline warhead 168
Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma cells 168
Cross-Metathesis Reactions in the Synthesis of Constrained Dipeptide Mimics as Potent Falcipain-2 Inhibitors. 166
Cross-Metathesis Reactions in the Synthesis of Constrained Dipeptide Mimics as Potent Falcipain-2 Inhibitors 162
Development of novel 1,4-benzodiazepine-based Michael acceptors as antitrypanosomal agents 159
A novel benzodiazepine derivative that suppresses microtubule dynamics and impairs mitotic progression 158
Design and NMR conformational analysis in solution of β5i-selective inhibitors of immunoproteasome 157
DEVELOPMENT OF NOVEL PEPTIDOMIMETIC ANALOGUES OF A HIGHLY POTENT AND SELECTIVE FALCIPAIN-2 INHIBITOR CONTANING A VINYL ESTER MOIETY 156
Design, synthesis and molecular modeling studies on peptidomimetic vinyl esters as falcipan-2 inhibitors 156
Synthesis and biological evaluation of novel peptidomimetics as rhodesain inhibitors 155
Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening 155
Chloro-substituted Hoveyda-Grubbs ruthenium carbene: Investigation of electronic effects 154
Development of novel irreversible rhodesain inhibitors as antitrypanosomal agents. 151
Development of novel dipeptide nitriles as inhibitors of rhodesain of Trypanosoma brucei rhodesiense 150
Development of Urea-Bond-Containing Michael Acceptors as Antitrypanosomal Agents Targeting Rhodesain 149
Chloro-substituted Hoveyda-Grubbs ruthenium carbene: investigation of electronic effects 149
Design and synthesis of novel isoxazole-based HDAC inhibitors 149
Development of novel amides as non covalent inhibitors of immunoproteasome 148
Development of novel benzodiazepine-based peptidomimetics as inhibitors of rhodesain of Trypanosoma brucei rhodesiense 147
Evaluation of curcumin irreversibility 146
G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitors: Current Trends and Future Perspectives 143
A novel 2,3-benzodiazepine-4-one derivative AMPA antagonist inhibits G2/M transition and induces apoptosis in human leukemia Jurkat T cell line 143
Falcipain-2 inhibitors 141
Drug combination studies of curcumin and genistein against rhodesain of Trypanosoma brucei rhodesiense 141
Development of pyridin-2-one derivatives as non-covalent inhibitors of immunoproteasome 140
Formation of 3-Aminofuran-2-(5H)-ones and 3-Amino-1H-pyrrole-2,5-diones by Rearrangement of Isoxazolidines 139
Composti antitumorali 138
Discovery of novel peptidomimetics containing a benzodiazepine scaffold as inhibitors of rhodesain of Trypanosoma brucei rhodesiense 138
Role of the microbiota in hematologic malignancies. 138
Development of Novel Peptidomimetics Containing a VinylSulfone Moiety as Proteasome Inhibitors 138
Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. 137
Development of novel 1,4-benzodiazepines as antitrypanosomal agents 136
Identification of novel 5 arylidene-3-phenyl-2 thioxoimidazolidin-4-ones as inhibitors of the chymotrypsin-like activities of the constitutive and immuno-proteasomes 136
Development of novel dipeptide nitriles as inhibitors of rhodesain of Trypanosoma brucei hodesiense 136
Drug combination studies of isoquinolinone AM12 with curcumin or quercetin: a new combination strategy to synergistically inhibit 20S proteasome 135
Novel peptidomimetics containing different α,β-unsaturated electrophilic functions, as falcipain-2 inhibitors 133
Alarmins and MicroRNAs, a New Axis in the Genesis of Respiratory Diseases: Possible Therapeutic Implications 132
Development of novel N-3-bromoisoxazolin-5-yl substituted 2,3-benzodiazepines as noncompetitive AMPAR antagonists 129
Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases 128
Cross-metathesis reactions applications to the synthesis of peptidomimetics as potent falcipain-2 inhibitors 127
Development of novel peptide-based Michael acceptors as antitrypanosomal agents 127
Optimization Strategy of Novel Peptide-Based Michael Acceptors for the Treatment of Human African Trypanosomiasis 126
Development of isoquinolinone derivatives as immunoproteasome inhibitors. 126
Design, synthesis and biological evaluation of peptidomimetics boronic acids targeting 20S proteasome 125
Peptidomimetics containing a vinyl ketone warhead as falcipain-2 inhibitors 122
Development of peptidomimetic boronates as proteasome inhibitors 121
Development of Novel Selective Peptidomimetics Containing a Boronic Acid Moiety, Targeting the 20S Proteasome as Anticancer Agents 121
Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation 121
Blunting Neuroinflammation by Targeting the Immunoproteasome with Novel Amide Derivatives 120
Development of peptidomimetic boronates as proteasome inhibitors 120
Glutamate Binding-Site Ligands of NMDA Receptors 119
Development of Novel Peptide-based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs) 119
Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors 117
DEVELOPMENT OF NOVEL PEPTIDOMIMETICS CONTAINIG A VINYL SULFONE MOIETY AS PROTEASOME INHIBITORS 117
Development of Novel Benzodiazepine-Based Peptidomimetics as Inhibitors of Rhodesain from Trypanosoma brucei rhodesiense 117
The Inhibition of Cysteine Proteases Rhodesain and TbCatB: A Valuable Approach to Treat Human African Trypanosomiasis 116
Mechanism of Inhibition of the GluA2 AMPA Receptor Channel Opening: The Role of 4-Methyl versus 4-Carbonyl Group on the Diazepine Ring of 2,3-Benzodiazepine Derivatives 115
Development of peptidyl Michael acceptors for S3 pocket investigation of rhodesain, cysteine protease of Trypanosoma brucei rhodesiense 114
Novel peptidomimetics as antiplasmodial falcipain-2 inhibitors 113
Synthesis and Molecular Modeling Studies of Derivatives of a Highly Potent Peptidomimetic Vinyl Ester as Falcipain-2 Inhibitors 113
Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine proteases falcipain-2 and rhodesain 112
A proteomic platform unveils the brain glycogen phosphorylase as a potential metabolic target for glioblastoma multiforme 112
Development of reduced peptide bond pseudopeptide Michael acceptors for the treatment of Human African Trypanosomiasis 111
Development of novel peptidyl nitriles targeting rhodesain and falcipain-2 for the treatment of sleeping sickness and malaria 110
Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors 110
Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors 110
Development of novel peptide-based Michael acceptors targeting rhodesain and falcipain-2 for the treatment of neglected tropical diseases (NTDs) 110
Reazioni di cross metathesis: applicazione alla sintesi di peptidomimetici potenziali inibitori di falcipaina-2 109
DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF PEPTIDOMIMETIC FALCIPAIN-2 INHIBITORS AS ANTIMALARIAL AGENTS 109
Drug repositioning for the treatment of hematologic disease: limits, challenges and future perspectives 109
Dipeptide nitrile CD34 with curcumin: a new improved combination strategy to synergistically inhibit rhodesain of Trypanosoma brucei rhodesiense 109
Development of nonpeptidic vinyl and allyl phosphonates as active-site-directed inhibitors of falcipain-2 107
Discovery of novel antitrypanosomal agents: design, synthesis of novel benzodiazepine-based peptidomimetics targeting rhodesain, the main cysteine protease of Trypanosoma brucei rhodesiense 107
Synthesis and biological evaluation of new 2-amino-6-(trifluoromethoxy)benzoxazole derivatives, analogues of riluzole. 105
Nonpeptidic Vinyl and Allyl Phosphonates as Falcipain-2 Inhibitors 104
Monoclonal antibodies: the greatest resource to treat multiple myeloma 103
Novel peptidomimetic cysteine protease inhibitors as potential antimalarial agents 103
Peptidyl Vinyl Ketone Irreversible Inhibitors of Rhodesain: Modifications of the P2 Fragment 100
Synthesis of constrained dipeptide mimics containing the benzodiazepine scaffold 100
Identification of a new series of non-covalent proteasome inhibitors with selectivity for β5-subunits 100
Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors 99
Novel peptidomimetics containing a β-turn mimetic 1,4-Benzodiazepine scaffold as falcipain-2 inhibitors 99
Development of Peptidomimetics with a Vinyl Sulfone Warhead as Irreversible Falcipain-2 Inhibitors 99
Synthesis and anti-HIV activity evaluation of new phenyl ethyl thiourea (PET) derivatives 98
Recent Advances in Nanotherapeutics for Multiple Myeloma 98
Synthesis of Peptidomimetics with the Benzodiazepine Nucleus as beta-turn mimic 97
Formaldehyde exposure and acute myeloid leukemia: A review of the literature 96
Drug synergism: studies of combination of RK-52 and curcumin against rhodesain of Trypanosoma brucei rhodesiense 94
Novel Peptidomimetics Containing a Vinyl Ester Moiety as Highly Potent and Selective Falcipain-2 Inhibitors 93
Novel peptidomimetic cysteine protease inhibitors as antimalarial agents 93
Development of novel Michael acceptors targeting rhodesain as antitrypanosomal agents 93
Progettazione e sintesi di nuovi inibitori del proteasoma quali potenti agenti antitumorali 92
Drug combination studies of the dipeptide nitrile CD24 with curcumin: a new strategy to synergistically inhibit rhodesain of trypanosoma brucei rhodesiense 91
Lead discovery of SARS-CoV-2 main protease inhibitors through covalent docking-based virtual screening 91
Mechanism and Site of Inhibition of AMPA Receptors: Substitution of One and Two Methyl groups at the 4-Aminophenyl Ring of 2,3-Benzodiazepine and Implications in the “E” Site 91
Totale 12.767
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.707
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.707
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021170 0 0 0 0 0 0 0 0 0 107 29 34
2021/2022771 11 104 6 48 14 6 65 25 7 53 133 299
2022/20232.281 182 201 103 179 141 229 36 148 959 4 76 23
2023/2024589 69 72 41 143 55 48 6 8 3 62 33 49
2024/20252.463 41 21 44 157 92 56 75 460 676 175 236 430
2025/20267.966 306 531 538 656 689 1.792 1.082 1.054 1.018 300 0 0
Totale 16.160